Add to ORKGImpact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patient
Erythropoiesis-stimulating agents (ESA) are used to treat anemia in hemodialysis (HD) patients. We i...
Copyright © 2015 Elena Gonzalez et al.This is an open access article distributed under the Creative ...
Should we adjust erythrop agent dosage to postdialy ero é at treatment of anemia associated to chron...
The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and ...
<b><i>Background:</i></b> Hemodialysis (HD) patients occasionally experience minor asymptomatic elev...
Elevated C-reactive protein level in hemodialysis patients with moderate/severe uremic pruritus: a p...
Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patien...
Erythropoiesis-stimulating agent (ESA) responsiveness has been reported to be associated with increa...
Biomarkers of inflammation, especially C-reactive protein (CRP), have been consistently shown to pre...
Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patie...
Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patient
Background. Recent clinical trials in cancer patients trea-ted with erythropoiesis-stimulating agent...
Copyright © 2012 Wen-Sheng Liu et al. This is an open access article distributed under the Creative ...
Background. Cardiovascular disease (CVD) is com-mon in haemodialysis patients with chronic renal ins...
Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarl...
Erythropoiesis-stimulating agents (ESA) are used to treat anemia in hemodialysis (HD) patients. We i...
Copyright © 2015 Elena Gonzalez et al.This is an open access article distributed under the Creative ...
Should we adjust erythrop agent dosage to postdialy ero é at treatment of anemia associated to chron...
The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and ...
<b><i>Background:</i></b> Hemodialysis (HD) patients occasionally experience minor asymptomatic elev...
Elevated C-reactive protein level in hemodialysis patients with moderate/severe uremic pruritus: a p...
Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patien...
Erythropoiesis-stimulating agent (ESA) responsiveness has been reported to be associated with increa...
Biomarkers of inflammation, especially C-reactive protein (CRP), have been consistently shown to pre...
Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patie...
Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patient
Background. Recent clinical trials in cancer patients trea-ted with erythropoiesis-stimulating agent...
Copyright © 2012 Wen-Sheng Liu et al. This is an open access article distributed under the Creative ...
Background. Cardiovascular disease (CVD) is com-mon in haemodialysis patients with chronic renal ins...
Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarl...
Erythropoiesis-stimulating agents (ESA) are used to treat anemia in hemodialysis (HD) patients. We i...
Copyright © 2015 Elena Gonzalez et al.This is an open access article distributed under the Creative ...
Should we adjust erythrop agent dosage to postdialy ero é at treatment of anemia associated to chron...